RESEARCH SUMMARY

Thai diabetes app shows little extra HbA1c benefit over standard education

Moderate confidence
Some Concerns bias
Last updated May 7, 2026

Key takeaway:

In a 6-month randomized trial of 129 adults with uncontrolled type 2 diabetes, a Thai-language self-management app did not lower HbA1c more than standard education alone, although fasting plasma glucose improved in participants younger than 65 years.

Study at a glance

Study type

RCTs

duration

Medium-Term (3–12 mo)

Intervention

Rama App

Outcomes

HbA1c, Fasting Plasma Glucose, Self-management behaviors

Funding

Non-industry sponsored

What was studied

A Thai-language diabetes self-management app added to standard outpatient education.

What they found

  • HbA1c ↓ in both groups, with no clear added benefit from the app
  • Fasting plasma glucose ↓ in participants younger than 65 years using the app
  • DSMES score ↑ during follow-up in the app group

mainEffects

HbA1c ↓ in both groups, with no clear added benefit from the app

Fasting plasma glucose ↓ in participants younger than 65 years using the app

DSMES score ↑ during follow-up in the app group

Evidence Suggest

  • At 6 months, mean HbA1c was 7.8% in the app group and 8.1% in the control group, but the between-group difference was not statistically significant.
  • Fasting plasma glucose was significantly lower at 6 months in the subgroup younger than 65 years assigned to the app.
  • The intervention group showed significantly higher DSMES scores from baseline to 6 months, suggesting support for self-management behaviors.

Who this applies to

These findings apply most directly to adults with uncontrolled type 2 diabetes in outpatient care who can use a smartphone. The results are especially relevant to Thai or similar Asian settings where local food databases may improve the usefulness of nutrition tracking.

Keep in Mind

The app was tested on top of diabetes self-management education and support, not instead of it. Because both groups received education, the study mainly shows whether the app adds extra benefit beyond usual structured care. The main HbA1c result was not clearly different, and the strongest glucose signal appeared in a younger subgroup.

Between the Lines

  • This was a single-center study with 129 participants.
  • The trial was open label, so participant behavior may have been influenced by knowing group assignment.
  • Six-month analyses excluded participants with missing outcome data rather than using full intention-to-treat methods.
  • Average app adherence was moderate, which may have limited the size of any benefit.

Unlock Full Analysis

Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.

Already have an account?

Sources

guidelines

Facilitating positive health behaviors and well-being to improve health outcomes: Standards of Care in Diabetes—2025

This ADA guideline supports culturally tailored diabetes self-management education and behavior support, which matches the app’s goal of helping people manage daily routines, diet, monitoring, and other self-care tasks.
guidelines

Abaloparatide Followed by Alendronate Shows Promising Results for Women With Osteoporosis, T2D | American Association of Clinical Endocrinology

Abaloparatide followed by alendronate treatment may improve bone mineral density (BMD) in women with postmenopausal osteoporosis and type 2 diabetes (T2D), according to study results presented at the AACE 28th Annual Scientific & Clinical Congress.
guidelines

Connecting the Dots: Diabetes, CKD, and CVD Pathways | American Association of Clinical Endocrinology

Connecting the Dots: Diabetes, CKD, and CVD Pathways enhances clinical understanding of the interconnected conditions of type 2 diabetes (T2D), chronic kidney disease (CKD), and cardiovascular disease (CVD). Strengthen recognition of shared pathophysiology, apply evidence-based risk assessment and treatment strategies, and improve care coordination through timely and appropriate referrals to drive better outcomes for patients with complex cardiometabolic conditions with this FREE course.
guidelines

Episode 39: AACE 2023 Updated Comprehensive Type 2 Diabetes Management Algorithm | American Association of Clinical Endocrinology

Listen to AACE podcast episode 39 to learn about the latest updates to AACE’s 2023 diabetes algorithm, which provides concise guidance to assist health care professionals in clinical decision-making for the management of Type 2 diabetes (T2D).
guidelines

Linagliptin Does Not Increase Adverse Renal Events in Patients With T2D, Kidney Disease | American Association of Clinical Endocrinology

Treatment with linagliptin in patients with type 2 diabetes (T2D) and cardiovascular and/or kidney disease had no impact on risk for cardiovascular or kidney events or hospitalization for heart failure, according to results of the CARMELINA study (Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus) presented at the AACE 28th Annual Scientific & Clinic
guidelines

Non-Insulin Injectable Therapies for Diabetes Management | American Association of Clinical Endocrinology

An estimated 30.3 million Americans have type 2 diabetes (T2D), a complex, progressive disease that requires intensified treatment over time.1-3 The complexity of T2D management, coupled with the need to tailor treatment recommendations to individual patients, presents an ongoing clinical challenge. The number and variety of treatment options available for T2D has increased dramatically in the last 15 years, with several new drug classes emerging as safe and effective.2,4,5
healthAuthorities

mHealth: new horizons for health through mobile technologies

This World Health Organization report explains how mobile technologies can extend health support beyond clinics, giving broader public health context for diabetes self-management apps used in routine daily life.
healthAuthorities

Manage Blood Sugar

This CDC resource explains practical ways to manage blood sugar through monitoring, food choices, activity, and medication routines, which are the same daily behaviors this mobile app was designed to support.
studiesGroup

Comparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis.

2026
studiesGroup

Beyond insulin therapy: Comparing relative benefits of adding SGLT2 versus DPP4 inhibitors in poorly controlled type 2 diabetic patients: A systematic review and meta-analysis.

2026
studiesGroup

Comparative efficacy and safety of three fixed-ratio combination products in type 2 diabetes: A network meta-analysis.

2026
studiesGroup

The role of peripheral blood HIF-1α in pancreatic β-cell dysfunction and insulin resistance among patients with type 2 diabetes: a systematic review and meta-analysis.

2026
studiesGroup

Central obesity and glycaemic control in newly diagnosed type 2 diabetes mellitus patients: evidence from Uzbekistan.

2026

No ads. No tracking

A clean, privacy-first research experience.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.